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This study demonstrates that a booster dose of the virosome-
formulated, aluminum-free hepatitis A vaccine Epaxal (Berna
Biotech) is highly immunogenic in subjects who received a
single primary dose of this vaccine 18–54 months earlier.
There were no significant differences in geometric mean an-
tibody titers (GMTs) among subjects who received the
booster dose 18–29 months (GMT, 2330 mIU/mL), 30–41
months (GMT, 2395 mIU/mL), or 42–54 months (GMT, 2432
mIU/mL) after primary vaccination, indicating that delays
in the administration of booster vaccination do not lead to
a loss of immunogenicity.
Hepatitis A is an acute, usually self-limiting infection caused
by hepatitis A virus (HAV). In areas of high endemicity, such
as Africa and parts of Asia and Latin America, infection with
HAV primarily occurs during childhood, which provides life-
long immunity against the disease. However, adult travelers
from countries of low HAV endemicity who visit regions of
high endemicity are at risk of acquiring clinically symptomatic
infection, and it is therefore recommended that they receive
vaccination against HAV infection [1–3]. To obtain long-lasting
protection against HAV, 2 doses of vaccine, administered 6–18
months apart, are recommended [3]. In practice, however,
many travelers do not return within 18 months for booster
vaccination. Therefore, it is important to know how long
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the booster vaccination can be delayed without loss of
seroprotection.
Epaxal (Berna Biotech), the only aluminum-free anti-HAV
vaccine available, is based on formalin-inactivated HAV, which
is attached to the surface of special liposomes (virosomes).
These virosomes replace aluminum hydroxide as the adjuvant
principle. The virosomes contain the hemagglutinin antigen
from the influenza A virus, which physiologically enhances the
immune response to inactivated HAV [4, 5]. A single injection
of Epaxal has been shown to be safe, well tolerated, and highly
immunogenic [5–7]. The aim of this study was to investigate
the immunogenicity of Epaxal given as a booster dose 118
months after primary vaccination with the same vaccine in
healthy adult travelers.
Patients, materials, and methods. This open-label, non-
comparative, single-center study assessed the immunogenicity
and tolerability of a single booster dose of Epaxal in 115 healthy
men and women (age,18 years) who had undergone primary
vaccination with a single dose of Epaxal 18 months earlier.
Subjects who had previously undergone both primary and
booster vaccination against HAV infection; who had an acute
febrile illness, known immunodeficiency, or history of allergy
or atopy; who had participated in another study; or who were
pregnant or lactating were excluded from the study. Concom-
itant treatment with any immunosuppressive drug was also
prohibited, as was receipt of a blood transfusion, immuno-
globulins, or any investigational drug during the 3 months
before the study. The study was approved by the Ethics Com-
mittee of Basel (Basel, Switzerland) and was conducted in ac-
cordance with the Declaration of Helsinki. All subjects provided
written informed consent before entry into the study.
Eligible subjects were vaccinated with a single dose of Epaxal,
which was injected intramuscularly into the deltoid muscle of
the left or right upper arm. The vaccine was supplied in ready-
to-use syringes containing 0.5 mL of vaccine, which included
500 RIA units of HAV antigen, 10 mg of influenza A (H1N1)
hemagglutinin, and 350 mg of phospholipid. The inactivated,
whole HAV contained in Epaxal is derived from the HAV strain
RG-SB, purified from MRC-5 human diploid cell cultures, and
inactivated in formalin [4, 5].
Blood samples were obtained at baseline (before injection
[day 1]) and ∼1 month later (days 26–46) for measurement of
serum HAV antibody titers by EIA (Enzymun; Boehringer
Mannheim) at the University Children’s Hospital (Basel). Titers
were expressed as HAV antibody concentrations in mIU/mL.
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Figure 1. Scatterplot of log-transformed hepatitis A virus (HAV) an-
tibody titers after booster vaccination, as a function of the time between
primary and booster vaccination. aData for a 31-year-old man who re-
sponded to the booster dose with a titer of 31 mIU/mL only (see Results).
bData for a subject who participated in an earlier trial of primary vac-
cination 81 months before booster vaccination.
Solicited data on adverse events and spontaneously reported
adverse events were documented and assessed by the investi-
gator at each clinic visit (i.e., before vaccination [baseline] and
∼1 month later). Subjects completed a checklist for specific
local and systemic reactions, including pain/tenderness, hard-
ness, swelling/tumefaction, redness (diameter, 15 mm), head-
ache, fatigue, arthralgia, loss of appetite, and nausea, and re-
corded their axillary temperature over a 4-day period after
injection. The intensity of each adverse event was assessed using
a 4-point rating scale, as follows: 0 for “none,” 1 for “mild”
(i.e., event did not interfere with daily activities), 2 for “mod-
erate” (i.e., event interfered with daily activities), and 3 for
“severe” (i.e., event prohibited normal daily activities).
Subjects were evaluated if they had no evidence of prior HAV
infection (i.e., an anti-HAV titer of !7000 mIU/mL) before
receiving the booster dose of Epaxal, and subjects had HAV
antibody titers measured before and after receipt of this booster
dose. Seroprotection was defined as an HAV antibody titer of
20 mIU/mL. In exploratory analyses, an HAV antibody titer
of 10 mIU/mL was also considered seroprotective, which is
consistent with studies of another inactivated HAV vaccine,
Vaqta (Merck) [8]. Geometric mean titers (GMTs) and sero-
protection rates were summarized according to time interval
after primary vaccination. The effect of the time interval since
primary vaccination on the HAV antibody response was ana-
lyzed using logistic regression analysis. All subjects who received
the study vaccine and completed the follow-up were evaluated
for safety.
Results. One hundred seventeen subjects were enrolled, of
whom 115 (53 men and 62 women) completed the study and
were evaluable for safety. The mean age was 44.8 years (range,
20–70 years). One subject was withdrawn from the study be-
cause of a screening error, and 1 subject failed to attend a
follow-up assessment.
Ninety-seven subjects were evaluated for immunogenicity.
Eighteen subjects were excluded from efficacy evaluation: 16
subjects had evidence of prior HAV infection (anti-HAV titer
on day 1, 11,559–70,000 mIU/mL), the serum sample obtained
on day 1 was missing for 1 subject, and the date of primary
vaccination could not be confirmed for 1 subject.
Before booster vaccination, 89% and 67% of 36 subjects who
received the booster dose at 18–29 months had HAV antibody
titers of 10 or 20 mIU/mL, respectively. These HAV anti-
body titers were found in 91% and 77% of 34 subjects, re-
spectively, who received the booster dose at 30–41 months and
in 85% and 70% of 27 subjects, respectively, who received the
booster dose at 42–54 months. One month after booster vac-
cination, the GMT was 2385 mIU/mL for the whole group,
and seroprotection was achieved in 100% of subjects. Logistic
regression analysis showed that there were no statistically sig-
nificant differences in GMT between subjects who received the
booster dose 18–29 months (GMT, 2330 mIU/mL; 95% CI,
1538–3529 mIU/mL), 30–41 months (GMT, 2395 mIU/mL;
95% CI, 1563–3672 mIU/mL), or 42–54 months (GMT, 2432
mIU/mL; 95% CI, 1506–3928 mIU/mL) after the first dose—
that is, the immune response was independent of the time since
primary vaccination (figure 1).
The antibody titers of 1 vaccinee (see footnote a in figure
1) require comment. A 31-year-old man responded to the
booster dose with a titer of 31 mIU/mL only. Before receiving
the booster dose (36 months after the primary vaccination),
the antibody titer had decreased to 8 mIU/mL. A thorough
clinical and laboratory evaluation did not reveal any abnor-
malities. A third dose was given 17 months after the booster,
and, 6 weeks after the third dose, the titer was 261 mIU/mL.
At the same time, an anti–hepatitis B antibody titer of 11500
mIU/mL was recorded after receipt of a third dose of hepatitis
B vaccine. No factor (e.g., age or whether the subject smoked
or was overweight) that could explain this low response to anti-
HAV antigen was found in this apparently healthy subject.
Booster vaccination was well tolerated by all subjects. No
serious systemic or local adverse events were reported. The vast
majority of local adverse events were of mild intensity and
resolved later the same day. Local adverse events were reported
by 31% of subjects. The most common local events were pain
or tenderness (23% of subjects) and induration (17% of sub-
jects). Systemic adverse events were reported by 46% of sub-
jects. However, a considerable proportion (24%) of these sub-
jects reported the same adverse symptoms before booster
vaccination upon solicited questioning. Only 1 subject had an
increased axillary temperature (37.5C). The most frequently
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reported systemic symptoms at baseline and after vaccination
were fatigue, headache, and arthralgia.
Discussion. The results of this study demonstrate that a
delay of up to 54 months between primary vaccination and
receipt of a booster dose does not influence the immune re-
sponse to Epaxal. Seroprotection rates after primary vaccination
were similar in subjects who received the booster dose after
18–29, 30–41, or 42–54 months, suggesting that the rate of
decline in antibody response after priming did not increase
over time. A single booster dose of Epaxal induced a strong
antibody response in all groups, including subjects with HAV
antibody titers of !10 mIU/mL at enrollment, which suggests
that an anamnestic immunological response was effectively de-
veloped [9]. The booster vaccination with Epaxal was well tol-
erated in all groups. The observation that the interval between
administration of primary and booster vaccinations did not
have any influence on the immune response to the booster dose
are consistent with results from similar studies using an alu-
minum-adsorbed vaccine [10, 11].
The results of this study are of practical relevance for cli-
nicians in travel medicine, because they demonstrate that delays
in the administration of booster vaccination do not lead to loss
of immunogenicity. Many travelers return for booster vacci-
nation much later than the recommended 12 months, often
before new travel. The antibody response found in the present
study indicates that booster doses are highly immunogenic for
up to 4–5 years after primary vaccination.
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